ArticleBMC gastroenterology2025
Metabolic dysfunction, cirrhosis, and HCV genotype 3a drive type 2 diabetes risk in chronic hepatitis C: a Southern Chinese cohort study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChronic hepatitis C (CHC) is associated with an increased risk of type 2 diabetes mellitus (T2DM). However, regional variations in HCV genotypes and clinical characteristics may influence this association. This study aimed to investigate the association between chronic hepatitis C virus (CHC) infection and the development of T2DM in CHC patients in Southern China.
methodsA retrospective case-control cohort study analyzed 442 CHC patients (242 without T2DM, 200 with T2DM) from 2010 to 2018. Biochemical parameters, HCV genotypes, and clinical characteristics were compared. Multivariate logistic regression and ROC analysis were performed to evaluate predictors of T2DM.
resultsThe CHC + T2DM group exhibited significantly higher age (P < 0.001), BMI (P = 0.001), fasting blood glucose (P < 0.001), fasting insulin (P = 0.015), HOMA-IR (Homeostasis Model Assessment-Insulin Resistance) index (P < 0.001), transaminases alanine transaminase (ALT) (P < 0.001) and aspartate transaminase (AST) (P < 0.001), total bilirubin (P < 0.001), γ-Glutamyl Transferase (GGT) (P < 0.001), and cirrhosis prevalence (P < 0.001). Logistic regression analysis showed that age (OR: 1.09), fasting blood glucose (OR: 16.20), fasting insulin (OR: 1.23), HOMA-IR (OR: 0.48), and GGT (OR: 1.01), cirrhosis (OR: 15.32) and hypertension (OR: 31.00) were the risk factors of T2DM in CHC patients. HCV genotype distribution differed significantly between CHC and CHC + DM groups (P = 0.008), with genotype 3a more prevalent in CHC + DM (2.07% vs. 11.36%, P = 0.032). Receiver Operating Characteristic curve analysis highlighted fasting glucose (AUC = 0.904) as the strongest predictor.
conclusionAge, metabolic dysregulation, liver cirrhosis, hypertension, and HCV genotype 3a are key risk factors for T2DM in CHC patients. Early screening for glucose intolerance and genotype-specific interventions are critical in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.